Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)

Abstract

Abstract Background Functional impairment affects many patients with schizophrenia. Treatment with the long-acting injectable antipsychotic aripiprazole once-monthly (AOM) may help improve functioning. Objectives To explore changes in functioning in patients with schizophrenia who received AOM treatment in observational studies. Methods Here we report functional outcomes in the form of Global Assessment of Functioning (GAF) scores in a pooled analysis of data from two observational studies from Canada (NCT02131415) and Germany (vfa non-interventional studies registry 15960N). Data from 396 patients were analyzed. Results At baseline, the mean GAF score was 47.7 (SD 13.4). During 6 months of treatment with AOM, the mean GAF score increased to 59.4 (SD 15.8). Subgroups stratified by patient age (≤35 years/>35 years), sex, disease duration (≤5 years/>5 years) and disease severity at baseline had all significantly improved their GAF at month 6. 51.5% of the patients showed a GAF score increase of at least 10 points, which was regarded as clinically meaningful, and were considered responders. Conclusions These data show that treatment with AOM may help improve patient functioning in a routine treatment setting. Trial registration NCT02131415 (May 6, 2014), vfa non-interventional studies registry 15960N.

Keywords

• Schizophrenia
• Long-acting injectable
• Observational study
• Real-world evidence
• Aripiprazole once-monthly
• Functioning